InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Cleansing Notice - s708A(5)(e) of the Corporations Act 2001 2 Feb 2018 11:53AM $0.115 $0.420 risen by 265.22%
$18 December Quarterly Activity and Cashflow Report 31 Jan 2018 6:36PM $0.110 $0.420 risen by 281.82%
$18 Appendix 3Y - Change of Director's Interest Notice x 3 30 Jan 2018 1:14PM $0.118 $0.420 risen by 257.45%
$18 Conversion of Performance Rights - Appendix 3B 30 Jan 2018 1:12PM $0.118 $0.420 risen by 257.45%
$18 Initial GMP Certification for European Production Facility 25 Jan 2018 9:51AM $0.105 $0.420 risen by 300%
$18 Trading Halt 23 Jan 2018 12:22PM $0.105 $0.420 risen by 300%
$18 MXC Signs Exclusive Distribution Agreement with Cult Beauty 22 Jan 2018 9:57AM $0.100 $0.420 risen by 320%
$18 MXC Welcomes Federal Export Legislation 5 Jan 2018 10:09AM $0.105 $0.420 risen by 300%
$18 MGC Derma Launches CBD Herbal Psoriasis Cream 4 Jan 2018 10:19AM $0.084 $0.420 risen by 400%
$18 Response to ASX query 3 Jan 2018 4:48PM $0.094 $0.420 risen by 346.81%
$18 Appointment of Joint Company Secretary 2 Jan 2018 7:07PM $0.093 $0.420 risen by 351.61%
$18 MXC Operational Update 18 Dec 2017 10:06AM $0.078 $0.420 risen by 438.46%
$18 Exercise of 6.5c Listed Options - Appendix 3B 15 Dec 2017 2:51PM $0.079 $0.420 risen by 431.65%
$18 New Year Launch of MGC Derma CBD Psoriasis Cream Confirmed 14 Dec 2017 10:02AM $0.078 $0.420 risen by 438.46%
$18 Results of Annual General Meeting 22 Nov 2017 7:25PM $0.100 $0.420 risen by 320%
$18 Binding Agreement to Supply $1m CBD Extract Annually 22 Nov 2017 9:51AM $0.094 $0.420 risen by 346.81%
$18 Definitive Supply Agreement Executed with HL Pharma 20 Nov 2017 9:44AM $0.073 $0.420 risen by 475.34%
$18 First Varm Cosmo Binding Purchase Order Received 14 Nov 2017 10:39AM $0.075 $0.420 risen by 460%
$18 MXC Enters Multi $M Australian Pharma Market 1 Nov 2017 9:41AM $0.068 $0.420 risen by 517.65%
$18 September Quarterly Activity and Cashflow Report 1 Nov 2017 8:17AM $0.068 $0.420 risen by 517.65%
$18 First $8m Binding Cosmetics Sales Agreement Signed 30 Oct 2017 9:54AM $0.069 $0.420 risen by 508.70%
$18 $40 Million White-Label CBD Cosmetics Agreement Executed 20 Oct 2017 9:38AM $0.038 $0.420 risen by 1,005.26%
$18 MXC Botanic Division Operational Update 13 Oct 2017 9:36AM $0.041 $0.420 risen by 924.39%
$18 Notice of Annual General Meeting/Proxy Form 12 Oct 2017 5:10PM $0.041 $0.420 risen by 924.39%
$18 Appendix 4G and Corporate Governance Statement 12 Oct 2017 5:03PM $0.041 $0.420 risen by 924.39%

651 - 675 of 818 results

Page 27 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.